Metabolic differences of current thienopyridine antiplatelet agents

Author： Fareed Jawed   Jeske Walter   Thethi Indermohan  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.3, 2013-03, pp. : 307-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platelet Activation, and Antiplatelet Targets and Agents: Current and Novel Strategies

By Xiang Yao-Zu   Xia Ye   Gao Xiu-Mei   Shang Hong-Cai   Kang Li-Yuan   Zhang Bo-Li  

Drugs, Vol. 68, Iss. 12, 2008-01 ,pp. : 1647-1664

Adis International

Access to resources Recommend Favorite

Hypolipidaemic and antiplatelet agents

By Kaliszan Roman   Siluk Danuta   Chilmonczyk Zdzislaw  

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 8, 2001-08 ,pp. : 1301-1327

Informa Healthcare

Access to resources Recommend Favorite

Recent Advances in Antiplatelet Agents

By  

Current Medicinal Chemistry, Vol. 9, Iss. 5, 2002-03 ,pp. : 577-589

Bentham Science Publishers

Access to resources Recommend Favorite

Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes

By Jennings Lisa K  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, Iss. 4, 2005-12 ,pp. : 727-737

Informa Healthcare

Access to resources Recommend Favorite

Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies

By  

Current Pharmaceutical Design, Vol. 23, Iss. 9, 2017-04 ,pp. : 1406-1423

Bentham Science Publishers

Access to resources Recommend Favorite